Bacteriophages are the most abundant members of the microbiota and have the potential to shape gut bacterial communities. Changes to bacteriophage composition are associated with disease, but how phages impact mammalian health remains unclear.
In Brief
Bacteriophages are abundant components of the gut microbiota, but how they impact health and immunity is unknown. Gogokhia et al. report that bacteriophages activate IFN-g through a TLR9-dependent pathway and exacerbate colitis. Supporting this, increased abundance of bacteriophages in patients with ulcerative colitis correlates with mucosal IFN-g responses.
INTRODUCTION
Mammals are colonized with microorganisms from all three domains of life that have significant impacts on mammalian immunity and health (Gensollen et al., 2016) . A large component of our microbiota is not classified within these domains as they are unable to self-replicate. Intestinal viruses, while containing members that directly infect eukaryotic cells, are largely composed of bacteriophages that target bacteria (Cadwell, 2015; Reyes et al., 2010; Virgin, 2014) . In most ecosystems, bacteriophages outnumber bacteria by a factor of 10 and likely represent the most abundant foreign microorganism on the mammalian body (Suttle, 2005) . While many bacteriophages reside as prophages within their bacterial host, many are found as free phage virions embedded within the mucus layer and have been proposed to function to maintain the intestinal barrier by controlling invasive bacterial populations (Barr et al., 2013) .
Phages have been utilized as curative elements in a variety of infections; however, the success of these treatments has been variable, and therefore antibiotics have dominated the therapeutic landscape (Kutter et al., 2010; Tsonos et al., 2014) . With the rapid evolution of bacterial resistance to antibiotics, modulation of bacterial responses by phage has regained interest and is currently being tested in a variety of clinical and experimental settings (Bragg et al., 2014) . Many diseases such as inflammatory bowel disease (IBD) and colorectal cancer are hypothesized to arise from alterations in the resident microbiota, with specific causal organisms identified (Arthur et al., 2012; Palm et al., 2014; Rubinstein et al., 2013) . Based on this, bacteriophage-based therapies may emerge as a unique treatment option for diseases associated with the microbiota.
Bacteriophages are members of the resident gastrointestinal (GI) microbiota, and their composition is significantly different in individuals with IBD when compared to healthy controls (Lepage et al., 2008; Norman et al., 2015) . The most notable change is an increase in the order of bacteriophages, Caudovirales, within the intestine of individuals with Crohn's disease (CD) and ulcerative colitis (UC) (Norman et al., 2015; Wagner et al., 2013) . While these viruses do not directly infect the mammalian host, they possess many molecules that could potentially stimulate the immune system (Duerkop and Hooper, 2013; Gó rski et al., 2012; Kurzepa et al., 2009; Hodyra-Stefaniak et al., 2015; Tetz et al., 2017; Roach et al., 2017) . However, it remains unclear whether bacteriophage stimulation of immunity could have consequences on mammalian disease.
RESULTS

Isolation of Human-Associated Bacteriophages against
Adherent Invasive E. coli Perturbations to commensal microbes that result in an outgrowth of potentially harmful organisms are associated with colorectal cancer (Levy et al., 2017) . Adherent invasive Escherichia coli (AIEC) and Fusobacterium nucleatum are found on tumors in individuals with intestinal cancer (Kostic et al., 2013; Winter et al., 2013) . E. coli NC101, an AIEC, enhances the growth of intestinal tumors in animals that are prone to inflammation, such as IL-10 À/À mice (Arthur et al., 2012) , or in genetically susceptible, non-inflammatory models, such as the APC min mouse (Dejea et al., 2018) . Mutations in tumor suppressor adenomatous polyposis coli (APC) are a major initiating factor in the etiology of colorectal cancer in humans (Barker et al., 2009) . Disease in this model is significantly worsened by colonization with AIEC strains (Dejea et al., 2018) . To determine whether bacteriophages could be employed to target AIEC in colorectal cancer, we sought to isolate phages against AIEC from the human microbiota. We identified and sequenced several AIEC-specific bacteriophages from an individual with IBD and chose three that were easily propagated and purified (Figures 1A and S1) . Phage NC-A has Podoviridae short-tailed morphology and closely resembles E. coli phage T7. Phage NC-B is a temperate phage, also a member of the Podoviridae with a relatively rare elongated head morphology and a close relative of E. coli phages øEco32 and ECPB2 (Nho et al., 2012; Savalia et al., 2008) . Phage NC-G has the Myoviridae long-contractile-tailed morphology and is related to the well-studied T4-like phages ( Figure S2 ) (Grose and Casjens, 2014) . All of these phages belong to the order Caudovirales, consistent with this order of bacteriophages being increased in individuals with CD (Norman et al., 2015; Wagner et al., 2013) .
To verify that each phage, or the combination of phages, was able to reduce levels of AIEC in vivo, we associated germ-free (GF) mice with a small community of bacteria that included Bacteroides fragilis, Lactobacillus johnsonii, Bifidobacterium longum, and Clostridium symbiosum with E. coli NC101 and (B) Germ-free animals were colonized with a contrived community of five different organisms including E. coli NC101, Bacteroides fragilis, Lactobacillus johnsonii, Bifidobacterium longum, and Clostridium symbiosum and treated with either heat-killed or live E. coli phages in their drinking water for 24 h (indicated by arrows), and E. coli colonization was monitored overtime from the feces by plating. (C) Germ-free animals were placed on drinking water containing phages or vehicle control and subsequently colonized with E. coli NC101. Bacterial titers in feces were determined by plating on selective media. n = 6 animals per group. (D) Levels of E. coli NC101 from animals treated in (C) were determined by qRT-PCR in small intestinal luminal content. (E) Levels of E. coli NC101 from animals treated in (C) were determined by qRT-PCR in small intestinal tissue. Data are represented as mean ± SEM. * p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001 as determined by a Student's t test. See also Figures S1 and S2. subsequently treated with phages. A single delivery of the phage cocktail reduced the colonization of E. coli NC101 for a single day, at which point the bacteria quickly rebounded and became resistant to subsequent phage treatment ( Figure 1B) . However, continuous administration of phages in the drinking water was sufficient to persistently suppress bacterial growth in the lumen and at tissue sites ( Figures 1C-1E) .
A Bacteriophage Cocktail Can Prevent Exacerbated Intestinal Tumor Growth
Use of bacteriophages to target specific bacteria and alleviate disease has been successful in multiple settings (Chadha et al., 2016; Kutter et al., 2010; Roach et al., 2017) ; however, it has yet to be tested in experimental cancer models. Therefore, we sought to use purified phages to prevent tumor growth in a mouse model of bacteria-aggravated colorectal cancer. Bacteriophages were extensively purified using several methods to remove the residual contaminating lipopolysaccharide (LPS) that might be present from propagating the phage in its host (Szermer-Olearnik and Boraty nski, 2015) . The LPS concentration in phage preparations was monitored using multiple assays and was consistently just above background levels found within normal drinking water ( Figure S3A ). This residual level of LPS was not sufficient to stimulate bone-marrow-derived dendritic cells (BMDCs), which are known to detect very low levels of LPS ( Figure S3B ). Regardless, similar concentrations of LPS were added as a vehicle control throughout all experiments. Multiple reports have estimated that the relative bacteriophage load within the intestine is between 5 3 10 7 and 5 3 10 12 PFU (plaqueforming unit) per gram of feces (Breitbart et al., 2003; Lepage et al., 2008; Mills et al., 2013) . Based on this, we administered approximately a total of 3 3 10 7 PFUs per day. Composite E. coli phage or vehicle control was added to the drinking water of specific pathogen-free (SPF) mice, and the animals were colonized with E. coli NC101. Colonization of APC min mice with E. coli NC101 leads to worsened disease outcome (Figures 2A and 2B) . While APC min mice displayed no overall difference in the number of tumors that formed within the small intestine, colonization with E. coli NC101 resulted in a significant increase in large tumor formation (Figures 2A-2C ). Composite bacteriophage treatment in the absence of AIEC had no effect on tumor growth ( Figure 2B ). Importantly, bacteriophage treatment of AIEC-colonized APC min animals reduced E. coli colonization ( Figure 2D ). This reduction in E. coli NC101 colonization was associated with decreased tumor size and enhanced survival (Figures 2A-2C ). Supporting these results, transcriptomic analysis of the small intestinal tissues revealed a drastic downregulation of genes associated with colorectal cancer, tumor growth, metastasis, and invasion of GI cancer in animals treated with E. coli bacteriophages (Figure 2E ). These results demonstrate that continuous treatment with bacteriophages isolated from the human GI tract can effectively reduce target bacteria in the intestine and protect from an invasive bacteria-exacerbated colorectal cancer.
Bacteriophage-Treated Animals Display Heightened Immune Responses
Analysis of the gene expression profiling data showed that despite the global downregulation of genes associated with cancer, a large set of immune system transcripts and pathways were upregulated in phage-treated animals compared to control. Specifically, induction of both innate and adaptive immunity was upregulated in bacteriophage-treated animals ( Figure 2F ). Supporting this, there were small but significant increases in the percentage of CD4+ and CD8+ T cells in the mesenteric lymph nodes (MLNs) of bacteriophage-treated animals ( Figures  2G, 2H , S3C, and S3D). Additionally, there were fewer naive and increased activated CD4+ T cells in both the spleen and MLNs of APC min mice that underwent bacteriophage treatment (Figures 2I, 2J, . Two possibilities exist for the increased immune responses observed in bacteriophagetreated mice. The first is that bacteriophage-mediated lysis of E. coli releases multiple bacterial components that could stimulate immunity, while the second is that bacteriophages directly stimulate the mammalian immune system. While the latter has been speculated by multiple investigators, it has yet to be directly tested in vivo.
Bacteriophages Can Stimulate the Mammalian Immune System
A few reports have demonstrated that bacteriophage preparations can elicit the induction of mammalian cytokines in vitro.
In contrast, a more recent study has demonstrated that neutrophils are required to prevent the outgrowth of phage-resistant bacteria during phage therapy of a lung Pseudomonas infection but reported that a single pulse of phage alone did not elicit immune induction using RNA-seq (Roach et al., 2017) . Thus, whether bacteriophages can directly stimulate the immune response remains contentious and has yet to be definitively tested. Based on this, we administered the purified E. coli bacteriophage cocktail or a vehicle control to GF mice that are devoid of bacterial colonization. While temperate phages dominate the microbial landscape, free bacteriophage are found to be (B) Tumors over 8 mm diameter throughout the small intestine (SI) were counted 70 days post-treatment (n = 8 for non-E. coli NC101-colonized controls, n = 5 for phage-colonized control, n = 16 for vehicle-treated, and n = 20 animals for E. coli phage cocktail treated). The results of five independent experiments are summed.
(C) Gross appearance of APC min mouse small intestines treated with NC101 alone and NC101 with phage.
(D) E. coli NC101 levels in the SI tissue determined by qRT-PCR; n = 6/6 animals for vehicle-treated and phage-treated animals. embedded within the intestinal mucus during the steady state and have been reported to be transcytosed by intestinal epithelial cell lines (Barr et al., 2013; Nguyen et al., 2017) . Additionally, during intestinal colitis, there is an increase in the abundance of a phage that is not associated with its bacterial host (Duerkop et al., 2018; Norman et al., 2015) . These represent situations where bacteriophages residing outside of bacteria would be available to potentially stimulate immunity, making this a physiologically relevant experiment. Continuous phage treatment resulted in a steady level of live phages within the gut, indicating that bacteriophages survive the transition through the GI tract ( Figures S4A and S4B ). Consistent with previous reports, GF mice had significantly fewer CD4+ T cells within the Peyer's patches (PP) when compared to SPF mice (Mazmanian et al., 2005) , while GF animals treated with bacteriophages had proportions and numbers of CD4+ T cells similar to those found in SPF mice ( Figures 3A-3C ). Heat killing of bacteriophages dissociates intact phage virions, disrupting the capsid structure and denaturing DNA complexes present within the phage, while any residual LPS within the sample is heat stable (Hecker et al., 1994) . Therefore, heat-killed phage preparations were used to control for LPS and to determine whether intact, infectious particles were required for immune activation. Heat-killed phage preparations did not cause expansion of CD4+ T cells, which remained similar to the levels of CD4+ T cells in GF mice ( Figures  3A-3C ). Specific microbes within the gut have been demonstrated to impact CD4+ T cell development leading to differential induction of Th1, Th17, or Treg responses (Belkaid and Hand, 2014) . Bacteriophage treatment did not impact the development of Th17 or Treg cells in GF mice ( Figures 3D, 3G , 3H, and S4C-S4E); however, it significantly increased the proportion and number of IFN-g-producing T cells within the PP but not the spleen ( Figures 3D-3F ). This was observed in both outbred (Swiss Webster; Figure 3E ) and inbred animals (C57BL/6; Figure 3I) , indicating that this stimulation is not a nuanced phenotype of a particular mouse strain. A statistically significant increase in CD8+ T cells was also seen in bacteriophage-treated GF animals ( Figure 3J ). Similar results were attained for gut CD4+ and CD8+ T cells using the well-characterized T4 phage, supporting that induction of mammalian immune responses is not exclusive to the bacteriophages that we isolated from human stool . Norovirus replicates within eukaryotic cells and has been shown to correct the defective intestinal architecture in GF mice in a type 1 interferon-dependent manner (Kernbauer et al., 2014) . However, we find that bacteriophages do not correct these deficiencies ( Figures S5A and S5B) . Additionally, there was no induction of type 1 interferon-responsive genes, IFN-b, or MX-1 during phage treatment, suggesting that bacteriophages do not stimulate this pathway ( Figures  S5C and S5D ). Collectively, these results argue that bacteriophages can directly stimulate host immunity.
Bacteriophages Activate IFN-g Responses through TLR9
Since bacteriophages do not infect eukaryotic cells, we sought to understand the mechanism by which they could stimulate IFN-g using in vitro approaches. While multiple cell types produce IFN-g in vivo, such as ILCs and NKT cells, for these in vitro experiments we chose to focus on IFN-g produced by CD4+ T cells because these cells are readily isolated, and there are well-established methods to work with them in culture. Bacteriophages do not directly stimulate IFN-g production from T cells ( Figure S5E) . Generally, T cell responses are initiated by interactions with dendritic cells (DCs) in the gut, and DCs are known to directly sample and present antigens found within the intestine (Rescigno et al., 2001) . As additional controls, we also included heat-killed phages, and phages against the prominent gut commensals, Bacteroides thetaiotaomicron and the gram-positive commensal Lactobacillus plantarum. DCs preincubated with any type of bacteriophage significantly increased the production of IFN-g by CD4+ T cells ( Figure 4A ), indicating that bacteriophage recognition by DCs could stimulate IFN-g production. Intact bacteriophages harbor various capsid proteins and DNA within the capsid head that could mediate stimulation of the immune system. Bacteriophage treatment with EDTA causes release of DNA from the phage head, leaving the capsid empty but intact (Bauer et al., 2015) . Treatment of DCs with DNAase-treated empty capsid did not stimulate IFN-g in culture; however, an over 40-fold induction of IFN-g was initiated upon treatment of DCs with purified phage DNA ( Figure 4B ). This (A-C) Swiss Webster germ-free animals were treated with either vehicle control or the cocktail of three E. coli phages in their drinking water for 4 weeks. GF, germfree mice; SPF, specific pathogen-free mice; HK, heat-killed. Data are represented from the phage-treated animals (n = 23), the vehicle animals (n = 19), the germfree animals (n = 12), and the SPF animals (n = 5). These data are combined from at least four independent experiments. is consistent with a recent report that failed to detect immune responses against three T4 capsid proteins (Miernikiewicz et al., 2013) . Therefore, our results suggest that DC recognition of bacteriophage DNA can stimulate IFN-g. Several pattern recognition receptors (PRRs) function to recognize viruses and foreign nucleic acids (Medzhitov and Janeway, 2000) . These include the RIG-I-like receptors, Rig-I, MDA5, and LGP2, which act as sensors of viral replication within cells; TLR3, which is stimulated by double stranded RNA; and TLR9, which recognizes unmethylated CpG dinucleotides, a motif associated with microbial DNA (Kawai and Akira, 2008) . Bacteriophages cannot infect or replicate within eukaryotic hosts and therefore would not be recognized by the RIG-I machinery. Based on this, we focused on nucleic acid-sensing receptors. TLR3 and TLR9-deficient DCs were pulsed with the indicated bacteriophages and subsequently incubated with T cells. While induction of Th1 responses were readily induced in TLR3
À/À DCs in response to bacteriophage treatment, IFN-g production from T cells was completely lost when stimulated with TLR9 À/À DCs ( Figure 4A ). Similarly, incubation of purified phage DNA with TLR9 À/À -deficient DCs failed to stimulate IFN-g production ( Figure 4B ). The cytokine IL-12 is produced by DCs and is known to stimulate IFN-g from multiple cell types; therefore, we analyzed DC activation in response to bacteriophage treatment. E. coli phages induced the expression of several cytokines including IL-12, IL-6, IL-10, and IP-10 but not IL-1a, TNF-a, or the surface markers CD80 or CD86 over vehicle control . Induction of these genes was dependent on Myd88, an adaptor molecule downstream of most TLRs, consistent with recognition of bacteriophages through TLR9 ( Figure S6H ). Moreover, DCs were still activated in the absence of CD14, a molecule critical to the recognition of LPS, further supporting that residual LPS contamination in bacteriophage preparations was not responsible for the induction of immune responses (Dobrovolskaia and Vogel, 2002 ) ( Figure S5I ). Intact E. coli and L. plantarum phages potently induced IL-12 production in DCs that was blocked by the addition of a TLR9 chemical antagonist (Figure 4C) . Moreover, phage DNA and UV-treated phages but not DNA purified from DCs, heat-killed phages, or capsids stimulated IL-12 production from DCs ( Figure 4C ). Consistent with our results, UV-treated DNA has been reported to maintain the ability to activate TLR signaling ( Figure 4C ) (Harberts and Gaspari, 2013) . TLR9 is known to be an intracellular receptor that signals within endosomes. Based on this, intact bacteriophages or phage DNA would have to be taken up to stimulate host immune responses. Consistent with this, phages stained with a DNAbinding dye and subsequently incubated with DCs can be found within the cytoplasm of DCs ( Figure 4D ). These puncta were never detected in DCs incubated in the absence of phage and stained with the DNA dye, nor was histone-containing DNA (that would indicate DNA from the DC) ever detected as such puncta ( Figures 4D, 4E , and S6J). Importantly, bacteriophagemediated IL-12 production from DCs is lost in the presence of cytochalasin D, an inhibitor of actin polymerization that prevents endocytosis ( Figure 4C ). Therefore, our data demonstrate that bacteriophage DNA is required for activation of DCs through the intracellular receptor TLR9.
Bacteriophages Stimulate Commensal and Phage-Specific Immunity T cells are known to mount antigen-specific responses against bacterial, viral, commensal, or even self-antigens. Based on this, we tested whether bacteriophage recognition by DCs would lead to phage-specific responses or if bacteriophages could function as an adjuvant against other antigens within the gut. MHCII expression on DCs is required for bacteriophagemediated induction of IFN-g-producing cells ( Figure 5A ). OT-II T cells, which express the T cell receptor (TCR) that recognizes ovalbumin (OVA), was used as a source of T cells in our co-culture system. DCs were pre-pulsed with OVA and B. thetaiotaomicron, L. plantarum, or E. coli phages and subsequently incubated with OT-II T cells. Treatment with phages potently stimulated OVA-specific IFN-g production in a TLR9, but not a TLR3-dependent fashion, suggesting that bacteriophages directly stimulate immunity ( Figure 5B ). To directly test this in vivo, GF mice were mono-associated with B. fragilis expressing the OVA protein, allowing us to track antigen-specific responses against a commensal ( Figure 5C ) (Kubinak et al., 2015) . T cells were then isolated from animals treated with either vehicle-or phage-containing drinking water and subsequently re-stimulated with DCs pulsed with either OVA antigen or bacteriophage antigens ( Figure 5C ). Phage treatment did not influence the colonization levels of B. fragilis-OVA, further indicating the inability of these E. coli phages to lyse off-target bacteria ( Figure S7A ). Bacteriophage-treated animals had significantly increased OVA-specific IFN-g production that was not present in vehicle-treated animals ( Figure 5D ). Phage-specific IFN-g production was also significantly elevated in bacteriophage-treated mice ( Figure 5D ). Vehicle-treated mice exhibit a 4-fold induction of phage-specific IFN-g over media controls, consistent with levels of IFN-g observed in the previous in vitro experiments. However, bacteriophage-treated GF animals had an even greater induction of IFN-g in response to phage antigens, indicating that phage-specific responses are primed in vivo. Supporting this, anti-phage IgA can also be detected within the feces ( Figure 5E ). Collectively, these data demonstrate that bacteriophages within the gut can stimulate both phage-specific as well as non-specific immune responses and can thus enhance immunity against other organisms present within the gut.
Enhanced Bacteriophage Abundance Exacerbates
Intestinal Colitis through TLR9 and IFN-g IBD is a complex interaction between genetic susceptibility, environment, and microbiota (Manichanh et al., 2012; Vermeire et al., 2011) . Individuals with IBD possess a significant loss of bacterial diversity and a concomitant increase in bacteriophage diversity and abundance (Gevers et al., 2014; Norman et al., 2015) . More recent studies have shown that the bacteriophage community transitions to a stochastic dysbiosis during murine colitis (Duerkop et al., 2018) . Whether these changes to the bacteriophage community matter during intestinal colitis has yet to be tested. Individuals with IBD have a specific expansion in the richness and diversity of Caudovirales bacteriophages. Based on this, we utilized our bacteriophage cocktail, which contains Caudovirales phages, to artificially increase the levels of free bacteriophage within the gut to test a role for bacteriophages during intestinal colitis. Conventionally colonized SPF animals were provided drinking water containing the bacteriophage cocktail and subsequently induced for dextran sodium sulfate (DSS) colitis. Of note, our mouse colony is not associated with any detectable levels of E. coli as measured by colony formation on plates and 16s sequencing, and therefore, our phage cocktail should not induce lysis of any endogenous microbes ( Figure S7B ). Animals with colitis that had previously received the cocktail of E. coli bacteriophages lost significantly more weight than vehicle-treated mice and had worse histology scores ( Figures 6A-6C ). Additionally, there was an increase in the proportion and number of CD4+ and CD8+ T cells in the MLNs and significantly more of these cells exhibited an activated phenotype and more IFN-g-and IL-17a-producing T cells (Jacob et al., 2017; Moayyedi et al., 2015) . FMT increases microbial diversity in recipients irrespective of the clinical response, and it remains unclear if diversity or specific bacterial taxa are responsible for the clinical efficacy (Jacob et al., 2017) . We examined if differences in the intestinal bacteriophage community impact the clinical success of FMT in active UC patients. To this end, we performed total nucleic acid sequencing to detect the viral community in 20 individuals with active UC prior to and 4 weeks after receiving FMT (Figure 7A) . Comparison of bacteriophage communities detected by VirMAP (Ajami et al., 2018) between healthy donors and UC recipients revealed a significant increase in the relative abundance of Caudovirales bacteriophages in individuals with UC, consistent with recent findings ( Figure 7B ) (Frank et al., 2007) . Compared to patients that did not respond to therapy, patients who had a clinical response to FMT had a lower relative abundance of Caudovirales bacteriophages at the time of transplant( Figure 7C ). Furthermore, the relative abundance of Caudovirales in non-responders increased after FMT while no change was observed in responders ( Figure 7C ). Additionally, consistent with our mechanistic findings in mice, CD4+ T cell production of IFN-g from rectal mucosal biopsies show a positive correlation between IFN-g and the relative abundance of total viral reads as well as Caudiovirales specifically ( Figures  7D, S7J , and S7K). To validate our in vivo findings that colitis-associated bacteriophages can induce IFN-g-producing T cells, we isolated virus-like particles (VLPs) from healthy patients, active UC, and inactive UC in remission. DCs pulsed with UC-associated and healthy VLPs were co-cultured with naive CD4+ T cells. VLPs from active UC but not inactive UC or healthy controls caused activation of naive CD4+ T cells and potent induction of IFN-g ( Figure 7E ). Collectively, our studies have identified the functional evidence that commensal bacteriophage communities can directly exacerbate intestinal disease, and their abundance can correlate with success of FMT. 
DISCUSSION
There is mounting evidence that disturbances to the gut microbiota can lead to diseases such as IBD, and identification of bacterial members that influence disease outcome has been the focus of much research over the last decade. However, how fungal, archaeal, and viral members of the microbiota might affect IBD is less explored (Duerkop et al., 2018; Norman et al., 2015; Sokol et al., 2017) . Bacteriophage recognition by the mammalian immune system has been considered by many but only studied in a few limited settings (Dabrowska et al., 2005; Eriksson et al., 2009; Gó rski et al., 2012; Khan Mirzaei et al., 2014) . More importantly, mechanistic insight of phage recognition by mammalian immune systems and determination of the relevance of phages during disease has yet to be trialed in in vivo settings. Here, we dissect the molecular pathway by which bacteriophages influence mammalian immunity within the GI tract, where these organisms are found in the highest abundance. This is highly relevant to human health, as bacteriophage virions have been identified to be abundant within the intestinal mucus where they could be sampled by immune cells (Barr et al., 2013) . Additionally, recent reports have demonstrated that intestinal epithelial cell lines are capable of transcytosis of phage (Nguyen et al., 2017) . Either by direct uptake or transcytosis, bacteriophages translocate from barrier surfaces to systemic circulation (Breitbart et al., 2003; Duerr et al., 2004; Moustafa et al., 2017) and likely directly interact with immune cells. While our data demonstrate that IFN-g induction is required for bacteriophage-mediated exacerbation of colitis, multiple cells types are able to produce this cytokine. Here, we show that stimulation of DCs can influence IFN-g production from CD4+T cells in vitro; however, NKT, NK, CD8+ T cells, and ILCs can all produce IFN-g. Indeed, we see expansion of CD8+ T cells in phage-treated GF mice (Figure 3) , suggesting that bacteriophages can influence multiple cell types. As most of these cell types also express TLR9, it is likely that bacteriophages can activate these cells to contribute to exacerbation of colitis. Additionally, just as specific bacteria can be recognized by multiple immune pathways, bacteriophages likely stimulate several other mammalian receptors, such as cGAS-Sting, which function as sensors of cytosolic DNA. Therefore, it likely that bacteriophages will have a multi-faceted influence on mammalian immunity through a variety of pathways that should be an area of continued investigation.
Immune activation by bacteriophages could be physiologically relevant and context specific. As reported in many animal models, specific targeting of pathogenic bacteria by bacteriophages in the infectious setting can successfully reduce the bacterial burden and ameliorate disease. Here, we report the use of E. coli-specific bacteriophages to significantly reduce colonization by carcinogenic bacteria and increase survival of animals predisposed to colorectal cancer development. Bacteriophage treatment of APC min animals in the absence of E. coli colonization did not reduce tumor burden, suggesting that bacteriophage stimulated immunity is not sufficient to mount effective anti-tumor immunity in this setting. However, our data demonstrate that during chronic inflammatory diseases, expansion of bacteriophages could be detrimental. Supporting this, recent reports have indicated that individuals with CD display a significant increase in the abundance of bacteriophages within the order Caudovirales (Norman et al., 2015) . Given that bacteriophages can confer differential functions to bacterial populations (i.e., antibiotic resistance), it is interesting to speculate that unique bacteriophages are present in diseased individuals. A recent study supports this, as they identified that Enterobacteriaceae-specific phages were enriched in animals during colitis (Duerkop et al., 2018) . Our data indicate that these organisms can be functionally relevant during intestinal disease as the presence of bacteriophages significantly enhance intestinal immune responses in a TLR9-dependent manner. Consistent with our findings in mice, we identify a positive correlation between mucosal IFN-g production and total viral abundance. Additionally, we show that VLPs isolated from UC patients with active disease but not inactive disease or healthy controls are capable of inducing potent IFN-g responses in vitro. Interestingly, Caudovirales bacteriophages are even more significantly enriched in individuals who fail to respond to a fecal transplant, which supports the notion that elevated Caudovirales phages might predict FMT failure and need for additional maintenance FMT delivery or escalation of treatment. Therefore, bacteriophages may act as a double-edged sword within the inflammatory environment of the gut. As immunity stimulated by bacteriophages is in part dependent on TLR9, antagonizing this pathway during phage therapy may ameliorate inflammatory responses against the phage itself. Given the specificity of bacteriophages for their bacterial targets and their influence on the mammalian intestine, future work is warranted to dissect how these complex interactions can be manipulated for therapeutic benefit.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
In Vivo Animal Studies
All experiments were performed with animals that were between 8 and 12 weeks of age. Both C57Bl/6 and Swiss Webster germfree mice were maintained in sterile flexible film isolators (CBC) at the University of Utah germfree facility. Sterility of the germfree isolators was monitored every month by microbiological plating under aerobic and anaerobic conditions and PCR amplification of conserved 16S rDNA using DNA extracted from the feces of multiple germfree mice in each chamber. The germfree colony was established using animals that were originally purchased from Taconic or University of Michigan. Breeder pairs of C57BL/6J-SPF animals were bred in our facility and age, gender matched littermate controls were used throughout the experiment. APC min , TLR3 -/-,
TLR9
-/-, MHCII -/-, OT II and IFNg -/-mice were purchased from The Jackson Laboratory. Animal procedures performed in this study were in compliance with federal regulations and guidelines set by the University of Utah's Institutional Animal Care and Use Committee (Protocol# 1704009). Experiments were replicated and either representative plots or combined data are presented in the manuscript where indicated. Simple randomization technique was used to select animals for each experimental groups. No specific sample sizes estimation was used, animals were allocated randomly and equally in the groups by the availability. Mice were assessed by staff veterinarian daily. Any animal that was reported for health status by the veterinarian was excluded from the experiments.
Human IBD Subjects
This prospective, open-label pilot study was registered with ClinicalTrials.gov (NCT02516384, IND 15988) and approved by IRB protocol 1404014982. Patients with active Ulcerative colitis were recruited from Jill Roberts Center for Inflammatory Bowel Disease. Informed consent was obtained from all study participants. Study population included male and female participants of >18 years of age with biopsy proven (Mayo score S 3 and endoscopic subscore S 1), inadequately controlled UC as defined by steroid dependence or the need for escalation of medical care. Patients were screened and those with Crohn's disease, infectious diarrhea, clinical conditions requiring emergency management, primary sclerosing cholangitis, pregnancy, history of FMT, antibiotic use within previous 2 months and recent malignancy, as well as other conditions deemed FMT unsafe for the patients were excluded from the trial. Donors were recruited by universal stool bank (OpenBiome) and screened rigorously. Two donor FMT material was prepared from individual frozen donor samples prior to the procedure. All patients meeting study enrollment criteria received standard PEG based colonoscopy bowel preparation and FMF material was delivered in the terminal ileum. 2 biopsy samples were obtained prior the FMT administration for cytokine and cellular analysis. Patients were followed post FMT by medical interview and physical exam at 2, 4 and 12 weeks. Fecal samples were collected at screening (Pre-FMT), week 2 and week 4 post FMT and flexible sigmoidoscopy was performed at the end of the study (week 4) to determine the response and remission, as well as obtain biopsy samples of rectal mucosa for cellular analysis. Primary endpoint of safety was determined by obtaining information about adverse events using open ended questions. Secondary endpoints included clinical response (DMayo score S3 and bleeding subscore & 1), clinical remission (Mayo score & 2 and no subscore > 1) and progression of disease (measured by initiation of biologics, escalation of dosage or colectomy).
Primary Murine Cells
Bone marrow was isolated from the femur and tibia of male C57Bl/6 and knockout animals by removing soft tissue from the bone using 70% ethanol-soaked paper towels and tweezers. The proximal end of the bone was exposed and the bone marrow was flushed using a 10mL syringe and 29G needle filled with complete RPMI. Single cell suspensions were centrifuged for 5 min at 1350 RPM followed by one-minute incubation with 5mL of RBC lysis buffer (Biolegend). 5mL of RPMI were added to inactivate the RBC lysis buffer and cells were subsequently centrifuged at 1350 rpm for 5 min followed by two washes in complete RPMI. 3x10 6 cells were plated in tissue culture dishes in complete RPMI media supplemented with 20ng/mL GM-CSF and incubated at 37 C. Cells in suspension were collected and placed in fresh media containing GM-CSF after 72 hours and incubated for an additional four days for a total of eight days. T cells were isolated from the spleen of male C57bl/6 mice by disrupting spleen tissue and passing through 100um cell strainer. Single cell suspension was incubated in RBC lysis buffer and washed twice in complete RPMI. CD4+ T cells were purified using a MACS column with negative selection according to manufacturer's instructions (Miltenyi Biotech).
Bacterial Strains and Plasmids
Bacteroides fragilis OVA expressing strain (Kubinak et al., 2015) was grown at in anaerobic chamber at 37 C for all experiments. Escherichia coli NC101 strain was provided by Dr. R. Balfour Sartor and was grown at 250rpm and 37 C shaker for all experiments. pACYC177 plasmid containing Ampicillin and Kanamycin resistance cassettes (provided by Matt Mulvey, University of Utah School of Medicine).
METHOD DETAILS Bacteriophage Isolation
Fecal samples from individuals diagnosed with Crohn's disease were obtained by Dr. John Valentine in the IBD clinic at the University of Utah hospital under approval by the IRB_00059476. Informed consent was obtained from the study patients. Upon arrival, samples were resuspended in 5mL of phosphate buffered saline (PBS) and stored at -80 C until use. The bacterial strain, Escherichia coli NC101, was used as an enrichment host to isolate bacteriophages, provided by Dr. R. Balfour Sartor. For phage isolation, the samples were thawed and an equal volume of HBSS supplemented with Ca 2+ and Mg 2+ (Corning Cellgro) was added. After incubation at room temperature for 2 hours, the samples were centrifuged for 20 minutes at 6000 rpm. Supernatant was collected and filtered through a 5mm filter followed by a 0.5mm filter. Five mLs of 10X LB broth (Fisher Bioreagents) 45 mL of fecal filtrate and a 1mL overnight culture of E. coli NC101 were combined and incubated with shaking at 37 C overnight. The following day 500uL chloroform (Fisher Chemical) was added to the overnight culture and shaken for 5 minutes. Cell debris was removed by centrifugation for 20 minutes at 6000 rpm. The supernatant was collected and centrifuged again overnight at 20 C 8000 rpm to pellet viral particles. The resulting supernatant was discarded and the pellet was resuspended in 5mL of HBSS supplemented with 1 mM Ca 2+ and Mg
2+
(Corning Cellgro). To remove lipopolysaccharide (LPS) and other bacterial products, the viral particles were further purified by a CsCl step density gradient centrifugation. For this, a gradient was produced using 10% sucrose, 1.4 g/cc and 1.6 g/cc CsCl into 14x89 mm Quickseal tubes (Beckmann). A 5mL viral suspension was carefully overlaid onto this gradient and subsequently ultracentrifuged for 2 hours at 4 C in a SW41 6236 rotor at 38,000 RPM (Model L8M, Beckman, Germany). The lower band at the 1.4/1.6 g/cc interface was collected using a syringe and hollow needle. To remove CsCl from phage preps, viral suspension was then dialyzed through 10K MWCO Snakeskin tubes (ThermoFisher Scientific) in HBSS supplemented with 1 mM Ca 2+ and Mg 2+ overnight at 4 C. Plaque assays were used to determine the concentration of phages. Phage solution was serially diluted and 100uL of each dilution was mixed with bacteria, 0.7% LB agar along with 100uL overnight culture of the host. The suspension was carefully distributed on the top of the LB agar plates and incubated overnight at 37 C. Phage titer was calculated by multiplying number of plaques by dilution factor.
Measurement of LPS Concentration
LPS concentration was measured using the LAL Chromogenic Endotoxin Quantitation Kit (Pierce) and EndoZyme (Hyglos HmbH,) according to the manufacturers protocol. The fluorescent signal and optical density were measured in a Synergy H1 microplate reader (Biotech). We chose LPS from E. coli O111:B4 as control since the bacteriophages used in the experiment were specific for E. coli. LPS in vehicle control was 0.5ng/mL of standard LPS from E. coli 0111:b4 (Invivogen).
Phage Sequencing
Phage DNA was isolated using Phage DNA Isolation Kit (Norgen) to prepare individually barcoded, MiSeq compatible, sequencing libraries was prepared using Illumina's (San Diego, CA) TruSeq DNA PCR-free sample prep kit. These libraries were pooled and run on a single MiSeq paired-end 300 cycle sequencing run. Raw reads were quality filtered and trimmed and TruSeq adapter filtered, using BBDuk (https://sourceforge.net/projects/bbmap/) with a minimum base quality threshold of 20 and a minimum trimmed read retention length of 100. Filtered reads were subsequently assembled using velvet assembler with a hash length of 121 and minimum contig length of 200 nucleotides. Assembled contigs were submitted for gene calling and annotation to PHANTOME and RAST, using the GeneMarkS gene caller. Sequencing was performed at the DNA Sequencing Core Facility, University of Utah.
Electron Microscopy
Negative stain transmission electron microscopy (TEM) was used for imaging purified phage preparations. A concentration of 10 13 PFU/mL of indicated phages were placed on a carbon-coated copper grid, washed with deionized H 2 O, stained with 1% uranyl acetate for 20 seconds and subsequently air dried. The specimen was blotted with filter paper between each step. Electron images were recorded by David Belnap on a FEI Tecnai 12 (Hillsboro, Oregon, USA) and JEOL JEM-1400 Plus (Tokyo, Japan) transmission electron microscope at the University of Utah Electron Microscopy Core laboratory.
Flow Cytometry
The spleen, MLNs and Peyer's patches (PPs) were mashed through 40mm cell strainers (Fisher Scientific) using Roswell Park Memorial Institute Medium (RPMI) without Ca 2+ or Mg 2+ (Corning Cellgro) supplemented with 10% FBS (HyClone), Pen/Strep (1%), sodium pyruvate (1%), 2.05mM L-glutamine (1%), non-essential amino acids (1%) and b-MercaptoEthanol (0.05mM) (complete RPMI) to obtain single cell suspensions. Cells were centrifuged at 1350 rpm for 5 minutes and subsequently resuspended in complete RPMI solution. For spleen lymphocyte isolation, cells were first incubated in RBC lysis buffer (TONBO Biosciences) for 3 minutes followed by the addition of 5mL of RPMI solution to deactivate the lysis buffer. For surface antibody staining, the cells were plated at 0.5x10 6 -1x10 6 cells per well in a 96-well plate and washed twice with sterile HBSS buffer supplemented with 2.5% FBS (FACS buffer). Cells were stained in 100uL of FACS buffer containing fluorescent antibody stains for 20 minutes in the dark at 4 C. Antibody concentrations are provided below. Cells were washed twice in FACS buffer to remove unbound antibodies and subsequently analyzed on a BD LSRFortessa flow cytometer. For intracellular stains, the cells were stimulated with ionomycin (500 ng/ml) (Sigma Aldrich), PMA (5 ng/ml) (Fisher Biosciences), and Brefeldin A (5 mg/ml) (Biolegend) for 4 hr at 37 C prior to staining. Stimulated cells were surface stained as described above and subsequently permeabilized and fixed in 100ml Perm/Fix buffer (eBiosciences) overnight. Cells were then washed one time with Perm/Wash buffer (eBiosciences) and stained with fluorescent antibodies diluted in Perm/Wash buffer (eBiosciences) for 30 min at 4 C. Cells were washed twice with 1X BD Perm/Wash buffer. Single, unstained and/or isotype controls were used in all experiments to set the appropriate gates. The following antibodies were used: anti-CD4 (eBioscience: clone RM4-5 FITC; eBioscience: clone GK1.5 APC; Biolegend: clone GK1.5 PE) 1:250, anti-CD3 (TONBO-biosciences: clone: 17A2 VioletFluor 450) 1:200, anti-CD8 (eBioscience: clone 53-6.7 PerCP-Cyanine5.5) 1:500, anti-CD62L (Biolegend: clone MEL-14 PE) 1:250, anti-CD69 (eBioscience: H1.2F3 PE/Cyanine7) 1:250. Following antibodies were used for intracellular cytokine staining: anti-Foxp3 (eBioscience: clone FJK-16 s APC/PerCP-Cy5.5) 1:100, anti-IL-17A (eBioscience: clone eBio17B7 eFluor 660; eBioscience: clone: eBio17B7 PE-Cyanine7) 1:100, or anti-IFN-g (Biolegend: clone XMG1.2 PE) 1:100.
Germ-Free Animal Experiments
Eight-week-old germ-free Swiss Webster animals were removed from the isolators and placed into sterile hepa filtered cages. Animals were provided drinking water supplemented with 50 mg/mL ampicillin (Fisher Scientific), neomycin (Fisher Scientific), erythromycin (Fisher Scientific) and gentamycin (GoldBio) and purified NC phages (3x10 7 PFU/mL) or vehicle control LPS. While animals were maintained under sterile conditions, addition of antibiotics was used as a precaution to prevent against bacterial contamination as has been described in (Round et al., 2011) . Animals maintained sterility throughout the entire experiment. Determination of NC phage killing efficiency in germfree mice Eight-week-old germfree mice were transferred to SPF conditions and provided 50mg/mL ampicillin and kanamycin within the drinking water supplemented with phage NC-A, NC-B, NC-G or a mixture of the three. Mice were subsequently orally gavaged with 100 mL 10 8 E. coli NC101 (Amp R ,Kan R ) bacterial suspension that was prepared by overnight culture in medium supplemented with 50mg/mL ampicillin and kanamycin. The next day the cells were washed twice with HBSS supplemented with Ca 2+ and Mg
2+
. Fecal pellets from infected mice were collected each day for 5 days and plated on MacConkey agar (BD Difco) containing 50mg/mL Ampicillin and Kanamycin to determine the level of colonization. DNA was isolated from small intestinal luminal content and 5 mm SI tissue sections to determine colonization of E. coli NC101 at the mucosa. DNA was extracted for bacterial quantification from fecal pellets using the PowerFecal DNA Isolation Kit (Qiagen). Bacteria were quantified with q-PCR using the protocol described in the section ''Quantitative real-time PCR'' using the following primers:
E. coli F 5-CATGCCGCGTGTATGAAGAA-3 and E. coli R 5-CGGGTAACGTCAATGAGCAAA-3.
APC min Cancer Model Experiment
4 weeks old APC min mice were provided the mixture of NC phages in drinking water without antibiotics as described above. Mice were maintained in this condition for 4 weeks, after which mice were challenged with 100 mL E. coli NC101 bacterial suspension via oral gavage biweekly for 2 weeks. Bacterial suspension was prepared with overnight culture of 10mL E. coli NC101. Next day the cells were washed twice with HBSS supplemented with Ca 2+ and Mg
2+
. Stabile colonization was confirmed by plating the fecal pellets on MacConckey agar. Mice were maintained on drinking water containing phage NC mixture for 2 months. Mice survival was monitored throughout the experiment. At the end of the experiment, mice organs were harvested as described above, as well as the number and size of intestinal polyps were counted. 5mm small intestinal snippets were collected for RNA extraction and bacterial quantification. Immune phenotyping of MLNs and Spleens were performed as described above.
Bone Marrow Dendritic Cell stimulation For stimulation of BMDCs as shown in Figure 3 , BMDCs were isolated as described above and incubated the phage cocktail at a MOI of 10 for 24 hours followed by analysis of the cells by ELISA or q-RTPCR.
Quantitative Real-Time PCR Expression of various cytokines was determined either with quantitative real-time PCR (Q-PCR) or ELISA. For RNA extraction, cells were resuspended in RiboZol RNA extraction reagent (Amresco) and frozen immediately at -20 C until further use. RNA isolation was performed with RNeasy kit (Qiagen) using manufacturer's instructions. Reverse transcription using the qScript cDNA superMix (Quanta Biosciences) was performed in accordance with the manufacturer's instructions. RT-qPCR was performed with LightCycler 480 SYBR Green I Master on a LightCycler 480 machine (Roche). The PCR protocol consisted of one cycle at 95 C (7.5 min) followed by 45 cycles of 95 C (10 sec) and 60 C (20 sec). Expression of ribosomal protein L32 was used as a standard. All primers used for the entire study are listed in Key Resources Table. Confocal Microscopy Purified phage particles were stained with 1:1000 SYBR Green (Thermo-Fisher) at 4 C for 15 min, followed by an incubation with PEG NaCl (5x) in the dark for 1 hour at 4 C to precipitate stained phage particles. Phages were centrifuged at 13,000 RPM for 3 min at 4 C and resuspended in sterile PBS; pellet was washed with sterile PBS twice to remove residual dye. BMDCs were isolated and stained with either Phalloidin-AlexaFluor680 (Thermo-Fisher) or Histone 2B-RFP (Thermo-Fisher) in blocking buffer (2% BSA, 0.1% Triton X-100, 0.1 M phosphate buffer, pH 7.4). Labeled BMDCs were mixed with stained phages at 1:100. Images were acquired using a Zeiss LSM800 confocal microscope.
ELISAs IL-1b, IL-10, IL-6, IP-10 and TNFa secretion were measured in cell culture supernatants using ELISA kits (eBioscience) according to the manufacturer's protocol.
Quantification of Phage Specific Antibodies
To quantify phage specific IgA antibodies, fecal pellets were collected and resuspended in 500ml sterile HBSS and spun at 2000 RPM for 5 minutes. Supernatants were placed in a new tube and spun again until samples were clear of bacterial pellet. Final supernatants were used as samples for an IgA specific ELISA kit (eBioscience). Phage specific IgA quantification was performed according to kit instructions with slight modification. Instead of coating plates with capture antibody specific for IgA, plates were coated overnight at 4 C with sonicated 10 12 phage particles in HBSS. Absorbance was read at 450nm and normalized to fecal weight.
Dendritic Cell -T Cell Co-culture Experiments Dendritic cells were isolated as described above and incubated with the phage cocktail at a MOI of 10 or 100 ug/mL OVA for 24 hours and subsequently washed with complete RPMI prior to incubation with T cells. CD4+T cells were isolated from the spleen of C57bl/6 mice and purified using a MACS columns with negative selection according to manufacturer's instructions (Miltenyi Biotech). 1x10 5 dendritic cells were incubated with 5x10 5 CD4+ T cells for 72 hours in a 24 well plate and cytokines were analyzed in the supernatant from these cultures by ELISA according to the manufacturer's protocols (eBioscience).
B. fragilis Mono-association Experiments
Eight-week-old germ-free B6 mice were removed from their flexible film isolators and transferred to sterile hepa filtered animal cages. To maintain sterility as described in (Round et al., 2011; Round and Mazmanian, 2010) , animals were provided 50mg/mL Erythromycin and Gentamycin in the drinking water supplemented with the NC phage mixture. Concurrently, mice were challenged with 100 mL 10 7 Bacteroides fragilis OVA expressing strain via oral gavage (Kubinak et al., 2015) . Equal colonization of mice with the bacteria was confirmed by plating the fecal samples. Mice were maintained in this condition for 4 weeks to ensure the mucosal immune response to the presence of bacteriophage particles. T cells were then isolated using the Miltenyi CD4 negative selection kit according to manufacturer's protocol (Miltenyi Biotech) and incubated with BMDCs that were primed for 24 hours with either phage or OVA peptide. Co-cultures were analyzed for IFN-g secretion by ELISA after 72 hours of co-culture.
DSS Colitis Experiments
Eight-week-old SPF C57Bl/6, TLR9 -/-, IFN-g -/-mice were provided a mixture of NC phages within the drinking water as described above. Mice were provided 2.5% DSS in the drinking water four weeks later. Animals were monitored for weight loss at the same time of day, each day for seven days. Animals were analyzed for histology and induction of immune responses within the MLN upon necropsy. Disease severity was scored on H&E stained colon samples by a blinded pathologist using the following scoring system: Both crypt loss and inflammation at the site was given its own score according to severity. 0, none; 1, very mild, 2, mild; 3, medium; 4 severe. The amount of colon affected by crypt loss or cellular infiltration was also taken into consideration: 1, 1 to 10%; 2, 10 to 20%; 3, 20 to 40%; 4, 40 to 60%; and 5, 60%-80%, 6, >80% for a maximum score of 20.
Viral Nucleic Acid Sequencing
Viral nucleic acids were extracted and sequencing libraries consisted of DNA and transcribed RNA. After extraction using the MagMax Viral RNA Isolation Kit (Thermo Fisher Scientific). Viral RNA was reverse transcribed using SuperScript II RT (Thermo, Fisher) and random hexamers. After short molecule and random hexamer removal with ChargeSwitch (Thermo Fisher), molecules were amplified and tagged with a BC 12 -V 8 A 2 construct using AccuPrime TM Taq polymerase and cleaned with ChargeSwitch kit. Viral amplicons were normalized, pooled, and made into an Illumina library without shearing. The library (150-600bp) was loaded in an Illumina HiSeq2000 (Illumina, Carlsbad, CA) and sequenced using the 2x100bp chemistry.
Human VLP Isolation
VLPs from fecal samples were purified as described previously (Reyes et al., 2010) with minor modification. Briefly, 5g of fecal samples were resuspended in 25mL PBS and centrifuged three times at 2500 g for 10 min. Final supernatant was sequentially passed through 40mm, 10mm, 1mm and 0.45mm filters to remove residual cells and byproduct and refilled to 25mL with sterile PBS. 4.14g CsCl was added to the filtrate to make the 1.12 g/ml -1 density solution. 5mL of the filtrate solution was deposited on the top of a 15-ml step gradient prepared using 5 ml CsCl solutions with respective densities of 1.7 g ml À1 , 1.5 g ml À1 and 1.35 g ml À1 SM buffer.
Samples were centrifuged for 3 hours at 60 000 g at 4C using SW32 swinging bucket rotor (Beckman). 1.5g ml -1 layer was recovered from the tube and dialyzed against PBS overnight.
QUANTIFICATION AND STATISTICAL ANALYSIS
Bacteriophage Sequencing Analysis Phages were classified according to the "cluster" method of Grose and Casjens (2014) where the strength of dot plot diagonal lines indicates the extent of overall genome sequence similarity. Dot plots comparing phage NC-A, NC-B and NC-G genome sequences to related phages were created with the computer program gepard and are shown in parts a, b and c of the figure, respectively. In each plot phage names are shown above and at the left, and colored circles indicate the genus of each phage's bacterial host. Red stars highlight the positions of phages NC-A, NC-B and NC-G. Thin red lines separate phage genome sequences, and thick red lines separate groups or "subclusters" of highly related phages. Representative phages from each of the subclusters are included in each plot; the phage names are sufficient to retrieve the sequences from GenBank database, and host species are given in the GenBank annotations. Each of the three phages characterized here falls unambiguously into a previously defined phage subcluster; NC-A lies in subcluster A of the T7-like phages, NC-B lies in subcluster A of the øEco32-like phages, and NC-G lies in subcluster C of the T4-like phages. These subclusters correspond approximately to the following genera defined by the International Committee of Taxonomy of Viruses (http://www.ictvonline.org/virustaxonomy.asp): T7virus, PhiEco32virus and Js98virus, respectively.
RNAseq
RNA was isolated using a Qiagen RNeasy kit (Qiagen) and sequenced by the University of Utah Sequencing Core Facility. Mouse ensemble annotations (build 74) were downloaded and converted to genePred format. Splice junction sequences were generated using USeq's (v8.8.8). Transcriptome application were made using a radius of 46. The splice junction sequences were added to the mouse chromosome sequences (mm10) and run through novoindex (v2.8) to create the transcriptome index. Reads were aligned to the transcriptome index described above using Novoalign (v2.08.03), allowing up to 50 alignments for each read. USeq's SamTranscriptomeParser application was used to select the best alignment for each read and convert the coordinates of reads aligning to splices back to genomic space. Read counts for each gene were generated using USeq's DefinedRegionDifferentialSeq application. These counts were used in DESeq2 to measure the differential expression between each condition. After RNAseq analysis, genes upregulated and downregulated by the treatment were subjected to Ingenuity Pathway Analysis (IPA, Qiagen). The Z scores produced by IPA quantify the bias between the number of significantly upregulated and downregulated genes in each pathway, weighing each gene according to the strength of its association with that pathway based on curated experimental findings. Genes used for this analysis were significantly (p<0.05) up or downregulated at least 1.5 fold.
VFMT Virome Analysis with VirMAP
Reads were demultiplexed into a sample bin using the barcode prefixing read-1 and read-2, allowing zero mismatches. Demultiplexed reads were further processed by trimming off barcodes, semi-random primer sequences, and Illumina adapters. This process utilized a custom demultiplexer and the BBDuk algorithm included in BBMap. The resulting trimmed dataset was analyzed using VirMAP. Briefly, VirMAP employs minimum set cover-based clustering algorithm and tiered mapping assembly using protein and nucleotide alignments to create putative viral genomes. VirMAP assigns taxonomies to reconstructed viral genomes using a scoring system that incorporates nucleotide and translated nucleotide alignment results in a per base fashion and optimizes for the highest resolution taxonomic rank with the widest breadth of database support.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 7. Results represent mean ± SEM and were analyzed by unpaired Students t test, One-way ANOVA with Mantel Cox or Bonferroni's Multiple Comparison Test as indicated in the figure legends. Number of animals used for each experiments is described in the corresponding methods or figure legends section. Significance was determined as p<0.05, **p<0.01, ***p<0.005, ****p<0.001.
DATA AND SOFTWARE AVAILABILITY
RNA-seq data have been deposited in GEO: GSE124123. The complete genome sequence of phages are available in the GenBank database under accession numbers NC-A: MK310182, NC-B; MK310183, and NC-G:MK310184.
